Centre Hospitalier Intercommunal De Mont De Marsan Et Du Pays Des Sources
- Address
- lock Available on a paid plan
Digestive System Diseases and Oncology Research
At Centre Hospitalier Intercommunal De Mont De Marsan Et Du Pays Des Sources, clinical research in digestive system diseases focuses on colon carcinoma and related cancer care, with studies aimed at improving treatment effectiveness and guiding follow-up for patients with detectable tumor markers.
- Evaluating whether treatment strategies can extend the time before disease progression in patients with colorectal cancer.
- Studying the role of circulating tumor DNA in identifying patients who may benefit from additional cancer therapy.
- Comparing standard cancer treatment approaches to better understand which options offer the most benefit after surgery and prior treatment.
This work supports more personalized care in oncology, especially for patients with high-risk disease who may need closer monitoring and tailored treatment decisions.
Nutritional and Metabolic Diseases Research
In the area of nutritional and metabolic diseases, the site is studying type 1 diabetes mellitus in children, adolescents, and young adults, with a focus on preserving the body's own insulin production after diagnosis.
- Testing a new therapy intended to help maintain endogenous insulin secretion in young people with newly diagnosed type 1 diabetes.
- Comparing active treatment with placebo alongside standard care to assess its effect on early disease control.
- Supporting research that may improve long-term management of diabetes by slowing the loss of natural insulin function.
These studies reflect a pediatric research interest in finding better ways to support children and adolescents living with metabolic disease and to improve early treatment outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 12 therapeutic areas and 15 of 108 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 105 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Unicancer4trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Intercommunal De Mont De Marsan Et Du Pays Des Sources
lock Showing 1 of 39 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 108 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 5 | Unknown | 2019-04-25 | 2025-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.